88768-40-5

Basic information

• Product Name: Cilazapril
• Synonyms: CILASTATIN NA;CILASTATIN SODIUM SALT;sodium hydrogen 7-[(2-amino-2-carboxylatoethyl)thio]-2-[[(2,2-dimethylcyclopropyl)carbonyl]amino]hept-2-enoate;6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid, 9-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]octahydro-10-oxo-, (1S,9S)-;6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid, 9-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]octahydro-10-oxo-, [1S-[1α,9α(R*)]]-;Ro 31-2848;Yipingshu;(1S,9S)-9-[(S)-1-Ethoxycarbonyl-3-phenylpropylamino]-10-oxoperhydropyridazino[1,2-a][1,2]diazepine-1-carboxylic acid
• CAS NO: 88768-40-5
• Molecular Formula: C₂₂H₃₁N₃O₅
• Molecular Weight: 417.5
• EINECS: 279-694-4
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;API
• Mol File: 88768-40-5.mol

Chemical Properties

• Melting Point: 95-97°C
• Boiling Point: 598.1 °C at 760 mmHg
• Flash Point: 315.5 °C
• Appearance: Off-White Solid
• Density: 1.26 g/cm³
• Vapor Pressure: 3.73E-15mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), Ethanol (Slightly, Sonicated), Methanol (Slightly)
• CAS DataBase Reference: Cilazapril(CAS DataBase Reference)
• NIST Chemistry Reference: Cilazapril(88768-40-5)
• EPA Substance Registry System: Cilazapril(88768-40-5)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• RTECS: MJ9650200
• Hazardous Substances Data: 88768-40-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Cilazapril is used as an ACE inhibitor for the treatment of hypertension. It is hydrolyzed in vivo to the active diacid metabolite, cilazaprilat, which helps in lowering blood pressure and managing hypertension in patients. Formulations containing cilazapril have been widely used in the treatment of hypertension, providing an effective therapeutic option for individuals suffering from high blood pressure.

InChI:InChI=1/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1

Upstream product

• 106860-19-9 (1S,9S)-t-butyl 9-<(1S)-ethoxycarbonyl-3-phenylpropylamino>octahydro-10-oxo-6H-pyridazino<1,2-a><1,2>diazepine-1-carboxylate 
• 29678-81-7 (R)-2-hydroxy4-phenylbutanoic acid 
• 90315-82-5 ethyl (R)-2-hydroxy-4-phenylbutyrate 
• 88767-98-0 ethyl (R)-4-phenyl-2-<<(trifluoromethyl)sulfonyl>oxy>butyrate 
• 106860-20-2 9-amino-octahydro-10-oxo-6H-pyridazo[1,2-a][1,2]diazepine-1-(S)carboxylic acid t-butyl ester 
• 88767-16-2 (S)-4-Chlorocarbonyl-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyric acid benzyl ester 
• 88784-33-2 (2S)-4-benzyloxicarbonyl-2-phthalimidobutanoic acid 
• 106928-72-7 (1S,9S)-t-butyl 1,2,3,4,7,8,9,10-octahydro-6,10-dioxo-9-phthalimidopyridazino<1,2-a><1,2>diazepine-1-carboxylate 
• 106927-97-3 (1S,9S)-t-butyl octahydro-10-oxo-9-phthalimido-6H-pyridazino<1,2-a><1,2>diazepine-1-carboxylate 
• 72064-51-8 (3S)-N¹-benzyloxycarbonyl-piperazic acid tert-butyl ester 
• 106860-13-3 (S)-2-[(S)-4-Benzyloxycarbonyl-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyryl]-tetrahydro-pyridazine-1,3-dicarboxylic acid 1-benzyl ester 3-tert-butyl ester 
• 88767-18-4 (S,S)-5-(6-(tert-butoxycarbonyl)tetrahydropyridazin-1(2H)-yl)-4-(1,3-dioxoisoindolin-2-yl)-5-oxopentanoic acid 

Downstream Products

• 64-17-5 ethanol 
• 90139-06-3 cilazaprilat 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF CILAZAPRIL

The present invention relates to a process for the preparation of optically pure (S,S)-6-t-butoxycarbonyl-hexahydro-1-pyridazinylcarbonyl-1,3-dioxo-2-isoindolebutyric acid, an intermediate for the preparation of cilazapril.

A NOVEL PROCESS FOR THE PREPARATION OF CILAZAPRIL

Cilazapril is prepared in good yield using ethyl R-2-(nitro or halo substituted benzene sulfonyloxy)-4-phenyl butyrate. Thus, (1S,9S)-t-butyl octahydro-10-oxo-9-amino-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate is reacted with ethyl R-2-(4-nitro benz

ENANTIOMERICALLY PURE CILAZAPRIL,PROCESS FOR PREPARATION

The invention relates to enantiomerically pure cilazapril and a process for preparing enantiomerically pure cilazapril. The invention also relates to pharmaceutical compositions that include the enantiomerically pure cilazapril and use of said composition

The Design and Synthesis of the Angiotensin Converting Enzyme Inhibitor Cilazapril and Related Bicyclic Compounds

The postulated binding functions for the active site of Angiotensin Converting Enzyme (A.C.E.), derived in an earlier study, have made possible the design of improved inhibitors.Consequently, (1S,9S)-9-octahydro-10-oxo-6H-pyridazodiazepine-1-carboxylic acid (Cilazapril), and related compounds, have been synthesized.They are very active inhibitors of A.C.E. and are highly potent antihypertensives in vivo.